Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in Louisiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 16 | 501 | 42% |
| 2020 | 7 | 368 | 45% |
| 2021 | 8 | 307 | 51% |
| 2022 | 10 | 394 | 54% |
| 2023 | 11 | 421 | 58% |
| 2024 | 10 | 385 | 60% |
| 2025 from claims | – | 399 323–469 | 61% |
| 2026 forecast | – | 401 314–504 | 62% |
| 2027 forecast | – | 405 301–536 | 63% |
| 2028 forecast | – | 410 290–565 | 63% |
| 2029 forecast | – | 414 281–593 | 64% |
| 2030 forecast | – | 418 274–620 | 65% |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Louisiana; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 48% hospital outpatient, 52% surgery center. The share outside the hospital has moved +13 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center |
|---|---|---|
| 2026 · ~400 | ~190 | ~220 |
| 2027 · ~410 | ~180 | ~220 |
| 2028 · ~410 | ~180 | ~220 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 55% (52% in 2025), hospital outpatient about 45% (48% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 99 | 3,368+0.4%/yr | +0.4%/yr | 1.4 | 71% | 4,030 in 2030+3.1%/yr |
| Florida | 48 | 1,901−2%/yr | −2%/yr | 0.8 | 65% | 2,240 in 2030+2.8%/yr |
| North Carolina | 27 | 1,005−2%/yr | −2%/yr | 0.9 | 45% | 950 in 2030−0.9%/yr |
| Tennessee | 22 | 830+1.8%/yr | +1.8%/yr | 1.1 | 70% | 1,040 in 2030+3.9%/yr |
| Georgia | 17 | 798−4.7%/yr | −4.7%/yr | 0.8 | 69% | 850 in 2030+1.1%/yr |
| Oklahoma | 21 | 734−3%/yr | −3%/yr | 1.4 | 45% | 850 in 2030+2.5%/yr |
| South Carolina | 21 | 702−4.7%/yr | −4.7%/yr | 1.0 | 36% | 710 in 2030+0.1%/yr |
| Maryland | 13 | 599+6.8%/yr | +6.8%/yr | 0.7 | 87% | 820 in 2030+5.5%/yr |
| Virginia | 13 | 494−4.5%/yr | −4.5%/yr | 0.4 | 18% | 600 in 2030+3.3%/yr |
| Mississippi | 10 | 380−3%/yr | −3%/yr | 1.0 | 72% | 490 in 2030+4.5%/yr |
| Kentucky | 7 | 342−3.7%/yr | −3.7%/yr | 0.7 | 42% | 480 in 2030+5.7%/yr |
| Arkansas | 11 | 302−2.5%/yr | −2.5%/yr | 0.7 | 51% | 330 in 2030+1.3%/yr |
| Alabama | 4 | 201−12%/yr | −12%/yr | 0.4 | 35% | 180 in 2030−1.6%/yr |
| West Virginia | 1 | 120−14%/yr | −14%/yr | 0.5 | 0% | 120 in 2030+0.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 95 | 8,745+0.5%/yr | +0.5%/yr | 20.31.5× | 63% | 10,700 in 2030+3.4%/yr |
| Peripheral nerve stimulation & intrathecal pumps | 4 | 441+6.5%/yr | +6.5%/yr | 1.00.7× | 46% | 410 in 2030−1.4%/yr |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in Louisiana · Every state · Compare with Texas
Pacira Pharmaceuticals leads with 42% of company spending on these surgeons in 2025, +4 pts on 2024.
In 2025, 9 companies reported engagement with Louisiana’s surgeons worth $290K in consulting, speaking, meals and travel tied to these products, about $29K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.